


## Default Question Block



OMB No.: 0925-0642

Expiration Date: 3/31/2026

*Public reporting burden for this collection of information is estimated to average 5 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0642. Do not return the completed form to this address.*

Thank you for attending the Rare Cancers Prevention and Interception Virtual Workshop, hosted by the National Cancer Institute (NCI) and Department of Defense (DoD) on May 7-8, 2024. This anonymous survey requests feedback on the virtual workshop and your interest in participating in future activities. All questions are optional, and you may exit this survey at any time.

What is your area of expertise?

How well did the workshop meet your expectations?

- ☐ Excellent
- ☐ Very good
- ☐ Good
- ☐ Fair
- ☐ Poor
- ☐ N/A



|  | Excellent             | Very Good             | Good                  | Fair                  | Poor                  | N/A                   |
|--|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| Overview of Rare Cancers: Current Status   | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| Emerging Opportunities for Rare Cancers Prevention and Interception                    | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| Networking - scientists, advocacy groups, and healthcare providers                     | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| Rare Cancers Clinical Trials Updates   | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| Challenges and Opportunities in Rare Cancers Research: Biology, Targets and Prevention | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |

In your opinion, what are the top 3 challenges for rare cancers research in general and prevention and interception research, specifically?

In your opinion, what are the ways to meet those challenges?

Any additional comments/thoughts.